AMENDMENTS TO THE CLAIMS

- 1. (Original) A microparticle comprising:
- (a) a core which comprises a water insoluble polymer or copolymer, and
- (b) a shell which comprises a hydrophilic polymer or copolymer and functional groups which are ionic or ionisable;

said microparticle having a disease-associated antigen adsorbed at the external surface.

- 2. (Original) A microparticle according to claim 1, wherein the disease-associated antigen is a microbial antigen or a cancer-associated antigen.
- 3. (Currently Amended) A microparticle according to claim 1-or 2, wherein the water insoluble polymer is poly(styrene).
- 4. (Currently Amended) A microparticle according to claim 1 or 2, wherein the water insoluble polymer is poly(methylmethacrylate).
- 5. (Currently Amended) A microparticle according to any one of the preceding claims claim 1, wherein the hydrophilic polymer is hemisuccinated polyvinylalcohol.
- 6. (Currently Amended) A microparticle according to any one of claims claim 1-to 4, wherein the hydrophilic copolymer is Eudragit® L100-55 (a copolymer of methyacrylic acid and ethyl acrylate).
- 7. (Currently Amended) A microparticle according to any of the preceding claims claim 1, wherein the particle has a maximum size of from 0.1 to 10μm.
- 8. (Currently Amended) A microparticle according to any of the preceding claims claim 1, wherein the antigen is a human immunodeficiency virus-1 (HIV-1) antigen.

- 9. (Original) A microparticle according to claim 8, wherein the antigen is HIV-1 Tat protein (SEQ ID NO: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30 or 32) or an immunogenic fragment thereof.
- 10. (Currently Amended) A method of production of a microparticle according to-any one of the preceding claims claim 1, said method comprising:
- (a) polymerizing one or more water insoluble monomers in the presence of one or more hydrophilic polymer by dispersion polymerization to form microparticles; and
 - (b) adsorbing a disease-associated antigen at the external surface of said microparticles.
- 11. (Currently Amended) A pharmaceutical composition comprising a microparticle according to any one of claims claim 1-to-9 and a pharmaceutically acceptable excipient.
- 12. (Currently Amended) A method of generating an immune response in an individual, said method comprising administering a microparticle according to any one of claims claim 1-to 9 or a pharmaceutical composition according to claim 11 in a therapeutically effective amount.
- 13. (Currently Amended) A method according to claim 12, wherein the antigen is a human immunodeficiency virus-1 (HIV-1) antigen and the microparticle is administered to the individual to prevent of preventing or treat treating HIV infection or AIDS, said method comprising administering a microparticle according to claim 8 or 9 in a therapeutically effective amount.

14-16. (Canceled).